Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL735732 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL10534546 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL6355287 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL275060 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL17941718 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL426431 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL15353579 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL16755696 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL151048 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL3178457 | 1.00 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4438120-A2 | METHODS FOR TREATING CLN2 DISEASE IN PEDIATRIC SUBJECTS | BioMarin Pharmaceutical Inc. (US) | 2024-10-02 | — | — | EP | claimed |
| EP-4021575-B1 | METHODS FOR TREATING CLN2 DISEASE IN PEDIATRIC SUBJECTS | BIOMARIN PHARM INC (US) | 2024-05-22 | — | — | EP | claimed |
| US-20220273775-A1 | Methods for Treating CLN2 Disease in Pediatric Subjects | BIOMARIN PHARMACEUTICAL INC. | 2022-09-01 | — | — | US | claimed |
| CN-114828960-A | Methods of treating CLN2 disease in pediatric subjects | 生物马林药物股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| EP-4021575-A1 | METHODS FOR TREATING CLN2 DISEASE IN PEDIATRIC SUBJECTS | BioMarin Pharmaceutical Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| CN-109569322-B | Super-hydrophilic and underwater super-oleophobic cellulose membrane and preparation method thereof | 内蒙古科技大学 | 2021-10-29 | — | — | CN | claimed |
| WO-2021042020-A1 | METHODS FOR TREATING CLN2 DISEASE IN PEDIATRIC SUBJECTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-03-04 | — | — | WO | claimed |
| CN-111893765-A | Cellulose/fibroin composite aerogel long fiber and preparation method thereof | 上海翔雍新材料科技有限公司 | 2020-11-06 | — | — | CN | claimed |
| WO-2025092324-A1 | ORNIDAZOLE PHOSPHATE CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 华创合成制药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025092323-A1 | CRYSTAL FORM I OF LEVORNIDAZOLE PHOSPHATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 华创合成制药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119818450-A | Pharmaceutical composition of levoketorolac and preparation method thereof | 南京海融医药科技股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2024230575-A1 | LEVORNIDAZOLE DISODIUM PHOSPHATE SOLVENT COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 华创合成制药股份有限公司 | 2024-11-14 | — | — | WO | disclosed |
| EP-4438120-A2 | METHODS FOR TREATING CLN2 DISEASE IN PEDIATRIC SUBJECTS | BioMarin Pharmaceutical Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240173296-A1 | PHARMACEUTICAL COMPOSITION OF (S)-KETOROLAC AND PREPARATION METHOD THEREFOR | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| CN-104610356-A | Stable phosphate crystal and preparation method thereof | NANJING HAILING PHARMACEUTICAL CO LTD OF YANGTZE RIVER PHARMACEUTICAL GROUP | 2015-05-13 | — | — | CN | disclosed |
| US-20150021512-A1 | SOFT MAGNETIC POWDER CORE | TDK CORPORATION (JP) | 2015-01-22 | — | — | US | disclosed |
| CN-102731571-A | Novel crystalline s-(-)-ornidazole phosphate disodium hydrate and application thereof | SHAANXI HECHENG PHARMACEUTICAL CO LTD | 2012-10-17 | — | — | CN | disclosed |
| CN-100391548-C | Water absorbent and producing method of same | NIPPON CATALYTIC CHEM IND (JP) | 2008-06-04 | — | — | CN | disclosed |
| CN-1856331-A | Water absorbent and producing method of same | NIPPON CATALYTIC CHEM IND (JP) | 2006-11-01 | — | — | CN | disclosed |
| US-5310469-A | Apparatus for quantitative analysis, dielectric housings, conductors for currents, membranes, substrates and molecules with active material attached | ABBOTT LABORATORIES (US) | 1994-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173296-A1 | PHARMACEUTICAL COMPOSITION OF (S)-KETOROLAC AND PREPARATION METHOD THEREFOR | SCN11A, PKLR, NOTUM | SLC34A1 365/4885KDM4E 2324/4885CYP2C19 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.